Evidence map›Paper›PMID 39296275›Full record

ArticleACS pharmacology & translational science2024

Novel Peripherally Selective Cannabinoid Receptor 1 Neutral Antagonist Improves Metabolic Dysfunction-Associated Steatotic Liver Disease in Mice.

Lucas T Laudermilk, Joel E Schlosburg, Elaine A Gay, Ann M Decker, Aaron Williams, Rubica Runton, Vineetha Vasukuttan, Archana Kotiya, George S Amato, Rangan Maitra

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lucas T LaudermilkCenter for Drug Discovery, RTI International, Research Triangle Park, North Carolina 27709-2194, United States.
Joel E SchlosburgDepartment of Pharmacology & Toxicology, Virginia Commonwealth University, Richmond, Virginia 23298-0565, United States.
Elaine A GayCenter for Drug Discovery, RTI International, Research Triangle Park, North Carolina 27709-2194, United States.
Ann M DeckerCenter for Drug Discovery, RTI International, Research Triangle Park, North Carolina 27709-2194, United States.ORCID https://orcid.org/0000-0003-1899-6558
Aaron WilliamsUndergraduate Studies, Clemson University, Clemson, South Carolina 29634, United States.
Rubica RuntonUndergraduate Studies, Georgia Institute of Technology, Atlanta, Georgia 30332-0002, United States.ORCID https://orcid.org/0009-0004-9695-2125
Vineetha VasukuttanCenter for Drug Discovery, RTI International, Research Triangle Park, North Carolina 27709-2194, United States.
Archana KotiyaCenter for Drug Discovery, RTI International, Research Triangle Park, North Carolina 27709-2194, United States.
George S AmatoCenter for Drug Discovery, RTI International, Research Triangle Park, North Carolina 27709-2194, United States.
Rangan MaitraCenter for Drug Discovery, RTI International, Research Triangle Park, North Carolina 27709-2194, United States.ORCID https://orcid.org/0000-0001-6663-6800

Funding

Investigation of Synthetic Cannabinoid Exposures and Pharmacological ConsequencesR01DA040460 · NIDA · RESEARCH TRIANGLE INSTITUTE · PI RANGAN MAITRA, Yanan Zhang · 2016 to 2026
$4.5M
Novel therapeutic approach for NASHR01DK124615 · NIDDK · RESEARCH TRIANGLE INSTITUTE · PI MAITRA, RANGAN · 2020 to 2023
$2.1M
Therapeutics Development for Hepatic FibrosisR01DK100414 · NIDDK · RESEARCH TRIANGLE INSTITUTE · PI MAITRA, RANGAN · 2014 to 2017
$1.8M
Therapeutic Strategy for NASHR41DK130765 · NIDDK · ARTIAM BIO INC. · PI SELTZMAN, HERBERT H · 2021 to 2021
$256k
NIDA NIH HHS R01 DA040460NIDDK NIH HHS R01 DK100414NIDDK NIH HHS R01 DK124615NIDDK NIH HHS R41 DK130765
6 · The paper itself

Abstract

The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing globally. MASLD is characterized by clinically significant liver steatosis, and a subset of patients progress to more severe metabolic-disorder-associated steatohepatitis (MASH) with liver inflammation and fibrosis. Cannabinoid receptor 1 (CB1) antagonism is a proven therapeutic strategy for the treatment of the phenotypes that underlie MASLD, though work on early centrally penetrant compounds largely ceased following adverse psychiatric indications in humans. We present here preclinical testing of a CB1 neutral antagonist,

Identifiers

PMID39296275
PMCPMC11406686

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.